Pioneering transformative breakthroughs that redefine discovery.
MISSION
Pioneering functional immunomics to uncover key immune cell pathways that will shape the future of next-generation immunotherapies for cancer and autoimmune diseases.
ABOUT
We approach discovery challenges such as identifying the unique pathways that regulate immune cytotoxicity in specific cancers with our proprietary Intelligent Design™ biotechnology, empowered by cutting-edge AI and our dedicated team of scientists, engineers, and clinicians.
Specializations
IMMUNOTHERAPY & PRECISION MEDICINE
-
CAR-T constructs design and optimization.
-
CAR-Treg constructs design and optimization.
-
Donor selection for allogeneic immunotherapies.
-
Derisking preclinical and clinical development.
-
Personalized immunotherapy.
Approach
PRECISION. PERSONALIZATION. INNOVATION.
At Feromics, we combine our Intelligent Design™ technology with deep biological insights to develop highly effective immunotherapy treatments. Our approach begins with the creation of proprietary libraries of interacting disease and immune cells divided by phenotypic functionalities such as cancer cell killing. Through the integration of AI and deep learning, we uncover novel, therapeutically relevant function-specific pathways that drive our product development and pipeline.
Partnerships
BETTER TOGETHER
Learn how our technology and team can empower discovery and help expand and strengthen immunotherapy pipelines.
Grants
SUPPORTING OUR RESEARCH
Awarded up to $4M 3-year contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop a precision medicine technology to improve patient treatment selection in cancer immunotherapy.
Under Contract No. 75N91024C00036 the Advanced Research Projects Agency for Health (ARPA-H), part of the Department of Health and Human Services, supports cutting-edge transformative biomedical and health breakthroughs.
OUR STORY
The story of Feromics began at the research laboratory of Professor Tania Konry at Northeastern University, where a team of engineers, biologists, and computer scientists took on the challenge of unlocking the therapeutic potential of immune cells for cancer treatment. This breakthrough effort resulted in novel biotechnology, over 52 scientific papers and patents, and collaboration with leading pharmaceutical companies. Joined by Dr. Shai Schubert as CEO in 2022, we spun out the technology to form Feromics with the mission of bringing transformative treatments to underserved patients.